clinical trial · NCT03897075
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Chronic Plaque PsoriasisModerate to Severe Nail PsoriasisTildrakizumabPlacebo
brief summary
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
started
May 13, 2021
primary completion
Apr 5, 2024
completion
Jan 30, 2025
last updated
Apr 1, 2026
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol